AbbVie, Caraway Therapeutics Team Up To Develop TMEM175 Modulators For Parkinson's Disease

AbbVie, Caraway Therapeutics Team Up To Develop TMEM175 Modulators For Parkinson's Disease
  • Caraway Therapeutics has entered into an exclusive collaboration and option agreement with AbbVie Inc ABBV to develop and commercialize Caraway's small molecule therapeutics targeting TMEM175.
  • Loss of function mutations in TMEM175 is associated with reduced lysosomal efficiency in a subpopulation of Parkinson's disease patients.
  • Under the terms of the agreement, Caraway will receive an upfront cash payment of $17 million.
  • After Caraway completes certain pre-clinical R&D activities for the collaboration program, AbbVie has an option to license the program and proceed into IND-enabling studies, clinical development, and commercialization.
  • Caraway is eligible to receive up to $267 million in payments, including upfront and future option payments and development milestones.
  • Caraway is a portfolio company of AbbVie Ventures.
  • Price Action: ABBV shares are down 0.12% at $112.21 in the premarket session on the last check Wednesday.
Posted In: BriefsParkinson’s DiseaseBiotechNewsHealth CareContractsGeneral